Comments on the ACD Received from the Public through the NICE Website

Name	[redacted]
Role	Pharmaceutical Industry
Other role	
Location	England
Conflict	no
Notes	Enzalutamide (Xtandi) is very expensive and does not represent value for money and should not be approved for public funding on the NHS. It does not have any proven benefits over the existing antiandrogen Bicalutamide (Casodex) which is much cheaper and already approved. Furthermore Xtandi is inferior to Zytiga which is the current standard of care for metastatic castrate resistant prostate cancer (mCRPC). Nice should also be careful of approving a drug which caused a high incidence of seizures in clinical trials.
Comments on individual sections of the ACD:	
Section 1 (Appraisal Committee's preliminary recommendations)	Enzalutamide not recommended for this indication since there are no proven benefits over Zytiga which can also be taken orally with food.
Section 2 (The technology)	Enzalutamide (Xtandi) is very expensive and represents poor value compared with the existing antiandrogen Bicalutamide (Casodex). No evidence is presented comparing Enzalutamide with Bicalutamide.
Section 3 (The manufacturer's submission)	This drug is inferior to the existing treatments Zytiga an Casodex and does not warrant NICE approval. Nice should also look more seriously at the serious side effects of this drug such as the high incidence of seizures in the clinical trials.